Stock Update (NASDAQ:DVAX): Dynavax Technologies Corporation Reports First Quarter 2015 Financial Results


Dynavax Technologies Corporation (NASDAQ:DVAX) reported financial results for the first quarter ended March 31, 2015.

The Company had $97.6 million in cash, cash equivalents and marketable securities as of March 31, 2015, compared to $122.7 million at December 31, 2014. Operating expenses of $27.1 million for the quarter ended March 31, 2015 increased by $2.4 million compared to the quarter ended December 31, 2014 primarily as a result of higher headcount and increased manufacturing expenses.

The net loss allocable to common stockholders for the quarter ended March 31, 2015 was $26.2 million, or $0.97 per basic and diluted share. The net loss allocable to common stockholders for the quarter ended December 31, 2014 was $22.3 million, or $0.85 per basic and diluted share. (Original Source)

Shares of Dynavax closed yesterday at $19.57 . DVAX has a 1-year high of $26.89 and a 1-year low of $12.50. The stock’s 50-day moving average is $22.57 and its 200-day moving average is $18.35.

On the ratings front, Dynavax¬†has been the subject of a number of recent research reports. In a report issued on March 23, J.P. Morgan analyst Anupam Rama upgraded DVAX to Buy, with a price target of $36, which represents a potential upside of 84.0% from where the stock is currently trading. Separately, on March 2, MLV & Co.’s Vernon Bernardino reiterated a Buy rating on the stock and has a price target of $25.

According to TipRanks.com, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Anupam Rama and Vernon Bernardino have a total average return of 56.0% and -13.7% respectively. Rama has a success rate of 66.7% and is ranked #672 out of 3594 analysts, while Bernardino has a success rate of 23.2% and is ranked #3559.

Dynavax Technologies Corp is a clinical-stage biopharmaceutical company. The Company is engaged in thedevelopment for the prevention of infectious disease, the treatment of autoimmune and inflammatory diseases, and the treatment of cancer.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts